This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Anti-CD23 mAb, IDEC-152
Description: IDEC-152 is a primatized monoclonal antibodythat targets the CD23 marker on specific immunecells. It has been well documented thatinterference with CD23 can inhibit the productionof Immunoglobulin E (IgE), the type of antibodythat contributes to asthma and various allergicdisorders.
Deal Structure: On April 25, 2002, IDEC extended its collaborative research agreement with Seikagaku Corporation to support the clinical development of IDEC-152. Financial terms of the entire collaborative agreement, including the extension, are valued at approximately $60 million.
Partners: Seikagaku Corporation
Pink Sheet chart: Biogen Idec Pipeline
Additional information available to subscribers only: